Origins of combination therapy for tuberculosis: Lessons for future antimicrobial development and application

mBio

Volumn 8, Issue 2, 2017, Pages

  Kerantzas, Christopher A ^a   Jacobs, William R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; ARSPHENAMINE; AZOSULFAMIDE; CARBAPENEM; CLAVULANIC ACID; CLOFAZIMINE; DACTINOMYCIN; ETHAMBUTOL; GLUCOSULFONE; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; PENICILLIN DERIVATIVE; PYRAZINAMIDE; RIFAMYCIN; STREPTOMYCIN; STREPTOTHRICIN; SULFAMIDOCHRYSOIDINE; SULFANILAMIDE; SULFAPYRIDINE; UNCLASSIFIED DRUG; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERICIDAL ACTIVITY; CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HIGH THROUGHPUT SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; COMBINATION DRUG THERAPY; DRUG DEVELOPMENT; HISTORY; PROCEDURES; TRENDS; UNITED KINGDOM;

AMINOSALICYLIC ACID; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; STREPTOMYCIN; TUBERCULOSIS; UNITED KINGDOM;

EID: 85019106609     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01586-16     Document Type: Review

References (89)

1. WHO. 2015. Global tuberculosis report 2015, p 1-126. World Health Organization, Geneva, Switzerland.
2. WHO. 1994. TB: A global emergency. World Health Organization, Geneva, Switzerland.
3. WHO. 2011. Tuberculosis control in the western Pacific region -2010 report. WPRO, Manila, Philippines.
4. Pyle MM. 1947. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Proc Staff Meet Mayo Clin 22:465-473.
5. Eldholm V, Balloux F. 2016. Antimicrobial resistance in Mycobacterium tuberculosis: the odd one out. Trends Microbiol 24:637-648. https://doi.org/10.1016/j.tim.2016.03.007.
6. Smith T, Wolff KA, Nguyen L. 2013. Molecular biology of drug resistance in Mycobacterium tuberculosis. Curr Top Microbiol Immunol 374:53-80. https://doi.org/10.1007/82_2012_279.
7. Schatz A, Bugle E, Waksman SA. 1944. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Exp Biol Med 55:66-69. https://doi.org/10.3181/00379727-55-14461.
8. Fleming A. 1929. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ. Br J Exp Pathol 10:226.
9. Lehmann J. 1946. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet i:15. https://doi.org/10.1016/S0140-6736(46)91185-3.
10. Williams KJ. 2009. The introduction of “chemotherapy” using arsphenamine— the first magic bullet. J R Soc Med 102:343-348.
11. Fox W, Ellard GA, Mitchison DA. 1999. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:S231-S279.
12. British Medical Journal. 1950. Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid; a Medical Research Council investigation. Br Med J 2:1073-1085. https://doi.org/10.1136/bmj.2.4688.1073.
13. Chain EB, Florey HW, Gardner AD, Heatley NG, Jennings MA, Orr-Ewing J, Sanders AG. 1940. Penicillin as a chemotherapeutic agent. Lancet 236:226-228. https://doi.org/10.1016/S0140-6736(01)08728-1.
14. Abraham EP, Chain EB, Fletcher CM, Gardner AD, Heatley NG, Jennings MA, Florey HW. 1941. Further observations on penicillin. Lancet 238: 177-189. https://doi.org/10.1016/S0140-6736(00)72122-2.
15. Samson RA, Hadlok R, Stolk AC. 1977. A taxonomic study of the Penicillium chrysogenum series. Antonie Van Leeuwenhoek 43:169-175. https://doi.org/10.1007/BF00395671.
16. Dubos RJ. 1939. Studies on a bactericidal agent extracted from a soil bacillus: I. Preparation of the agent. Its activity in vitro. J Exp Med 70:1-10. https://doi.org/10.1084/jem.70.1.1.
17. Dubos RJ. 1939. Studies on a bactericidal agent extracted from a soil bacillus: II. Protective effect of the bactericidal agent against experimental pneumococcus infections in mice. J Exp Med 70:11-17. https://doi.org/10.1084/jem.70.1.11.
18. Dubos RJ, Cattaneo C. 1939. Studies on a bactericidal agent extracted from a soil bacillus: III. Preparation and activity of a protein-free fraction. J Exp Med 70:249-256. https://doi.org/10.1084/jem.70.3.249.
19. Dubos RJ, Hotchkiss RD. 1941. The production of bactericidal substances by aerobic sporulating bacilli. J Exp Med 73:629-640. https://doi.org/10.1084/jem.73.5.629.
20. Shida O, Takagi H, Kadowaki K, Komagata K. 1996. Proposal for two new genera, Brevibacillus gen. nov. and Aneurinibacillus gen. Nov. Int J Syst Bacteriol 46:939-946. https://doi.org/10.1099/00207713-46-4-939.
21. Grossman CM. 2008. The first use of penicillin in the United States. Ann Intern Med 149:135-136. https://doi.org/10.7326/0003-4819-149-2-200807150-00009.
22. Florey ME, Adelaide MB, Florey HW, Adelaide MB. 1943. General and local administration of penicillin. Lancet 241:387-397. https://doi.org/10.1016/S0140-6736(00)41962-8.
23. Keefer CS, Blake FG, Marshall EK, Lockwood JS, Wood WB, Jr. 1943. Penicillin in the treatment of infections: a report of 500 cases. J Am Med Assoc 122:1217-1224. https://doi.org/10.1001/jama.1943.02840350 001001.
24. Richards AN. 1964. Production of penicillin in the United States (1941-1946). Nature 201:441-445. https://doi.org/10.1038/201441a0.
25. Waksman SA, Woodruff HB. 1941. Actinomyces antibioticus, a new soil organism antagonistic to pathogenic and non-pathogenic bacteria. J Bacteriol 42:231-249.
26. Waksman SA, Woodruff HB. 1942. Streptothricin, a new selective bacteriostatic and bactericidal agent, particularly active against Gramnegative bacteria. Exp Biol Med 49:207-210. https://doi.org/10.3181/ 00379727-49-13515.
27. Schatz A, Waksman SA. 1944. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Exp Biol Med 57:244-248. https://doi.org/10.3181/00379727-57-14769.
28. Robinson HJ, Smith DG, Graessle OE. 1944. Chemotherapeutic properties of streptomycin. Exp Biol Med 57:226-231. https://doi.org/10.3181/ 00379727-57-14763.
29. Feldman WH, Hinshaw HC. 1944. Effects of streptomycin on experimental tuberculosis in guinea pigs: a preliminary report. Proc Staff Meet Mayo Clin 19:593-599.
30. Hinshaw HC, Feldman WH. 1945. Streptomycin in treatment of clinical tuberculosis: a preliminary report. Proc Staff Meet Mayo Clin 20:313-318.
31. Riggins HM, Hinshaw HC. 1949. Streptomycin-tuberculosis research project of the American Trudeau Society; a summary report. Am Rev Tuberc 59:140-167.
32. Journal of the American Medical Association. 1947. The effects of streptomycin on tuberculosis in man. J Am Med Assoc 135:634-641.
33. Journal of the American Medical Association. 1948. Streptomycin in the treatment of tuberculosis. J Am Med Assoc 138:584-593.
34. Journal of the American Medical Association. 1950. Current status of the chemotherapy of tuberculosis in man; a summary report. J Am Med Assoc 142:650-653.
35. Journal of the American Medical Association. 1950. Streptomycin in the treatment of tuberculosis. J Am Med Assoc 142:654-655.
36. Journal of the American Medical Association. 1951. Chemotherapy of tuberculosis in man. J Am Med Assoc 147:253-258.
37. D’Esopo N. 1954. Chemotherapy of tuberculosis in man: present status. J Am Med Assoc 154:52-59.
38. King DS. 1955. Present status of the treatment of tuberculosis in man. J Am Med Assoc 158:829-831.
39. Wier JA. 1956. Present status of the treatment of tuberculosis. J Am Med Assoc 162:471-473. https://doi.org/10.1001/jama.1956.72970220011009.
40. Hinshaw HC, Feldman WH. 1946. Streptomycin in treatment of clinical and experimental tuberculosis. Ann N Y Acad Sci 48:175-182. https://doi.org/10.1111/j.1749-6632.1946.tb31761.x.
41. Mc Dermott W, Muschenheim C, Hadley SJ, Bunn PA, Gorman RV. 1947. Streptomycin in the treatment of tuberculosis in humans. (I. Meningitis and generalized hematogenous tuberculosis.) Ann Intern Med 27: 769-822. https://doi.org/10.7326/0003-4819-27-5-769.
42. Feldman WH, Hinshaw HC. 1948. Streptomycin; a valuable antituberculosis agent. Br Med J 1:87-92. https://doi.org/10.1136/bmj.1.4541.87.
43. Bunn PA. 1948. Streptomycin in the treatment of human tuberculosis. Chest 14:670-685. https://doi.org/10.1378/chest.14.5.670.
44. Pfuetze KH, Pyle MM. 1945. Streptomycin in the treatment of tuberculosis. J Am Med Assoc 139:634-639. https://doi.org/10.1001/jama.1949.02900270018005.
45. British Medical Journal. 1948. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. Br Med J 2:769-782. https://doi.org/10.1136/bmj.2.4582.769.
46. British Medical Journal. 1948. Streptomycin in pulmonary tuberculosis. Br Med J 2:790-791. https://doi.org/10.1136/bmj.2.4582.790.
47. British Medical Journal. 1948. The controlled therapeutic trial. Br Med J 2:791-792. https://doi.org/10.1136/bmj.2.4582.791.
48. Hart PD. 1999. A change in scientific approach: from alternation to randomised allocation in clinical trials in the 1940s. BMJ 319:572-573. https://doi.org/10.1136/bmj.319.7209.572.
49. Mitchison DA. 1950. Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis; results of simultaneous sensitivity tests in liquid and on solid media. Thorax 5:144-161. https://doi.org/10.1136/thx.5.2.144.
50. Ehrlich P. 1908. Experimental researches on specific therapy. On immunity with special relationship between distribution and action of antigens. Lewis Publishers, London, England.
51. Dubos J, Dubos RJ. 1952. The white plague. Little, Brown, Boston, MA.
52. Wainwright M. 1987. The history of the therapeutic use of crude penicillin. Med Hist 31:41-50. https://doi.org/10.1017/S0025727300046305.
53. Domagk G. 1935. Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Dtsch Med Wochenschr 61:250-253. https://doi.org/10.1055/s-0028-1129486.
54. Klee P, Römer H. 1935. Prontosil bei Streptokokkenerkrankungen. Dtsch Med Wochenschr 61:253-255. https://doi.org/10.1055/s-0028-1129487.
55. Hinshaw HC, Feldman WH. 1941. Treatment of experimental tuberculosis. J Am Med Assoc 117:1066-1068. https://doi.org/10.1001/jama.1941.02820390008003.
56. Bernheim F. 1940. The effect of salicylate on the oxygen uptake of the tubercle bacillus. Science 92:204-204. https://doi.org/10.1126/science.92.2383.204.
57. Dempsey TG, Logg MH. 1947. Para-aminosalicylic acid in tuberculosis; early results of clinical trials. Lancet 2:871. https://doi.org/10.1016/S0140-6736(47)90956-2.
58. O’Connor JA. 1948. Para-aminosalicylic acid in the treatment of tuberculosis. Postgrad Med J 24:455-462.https://doi.org/10.1136/pgmj.24.275.455.
59. British Medical Journal. 1950. The chemotherapy of tuberculosis. Br Med J 2:1102-1103. https://doi.org/10.1136/bmj.2.4688.1102.
60. Daniels M, Hill AB. 1952. Chemotherapy of pulmonary tuberculosis in young adults: an analysis of the combined results of three Medical Research Council trials. Br Med J 1:1162-1168. https://doi.org/10.1136/ bmj.1.4769.1162.
61. British Medical Journal. 1952. Chemotherapy of tuberculosis. Br Med J 1:1179-1180. https://doi.org/10.1136/bmj.1.4769.1179-a.
62. British Medical Journal. 1952. Prevention of streptomycin resistance by combined chemotherapy: a Medical Research Council investigation. Br Med J 1:1157-1162. https://doi.org/10.1136/bmj.1.4769.1157.
63. British Medical Journal. 1952. Isoniazid in pulmonary tuberculosis. Br Med J 2:764-765. https://doi.org/10.1136/bmj.2.4787.764.
64. Palaci M, Dietze R, Hadad DJ, Ribeiro FKC, Peres RL, Vinhas SA, Maciel ELN, do Valle Dettoni V, Horter L, Boom WH, Johnson JL, Eisenach KD. 2007. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 45:4064-4066. https://doi.org/ 10.1128/JCM.01780-07.
65. Schwartz JA. 1957. Comparative efficacy of the concurrent use of pyrazinamide and isoniazid with that of other forms of therapy in the treatment of pulmonary tuberculosis. Dis Chest 32:455-459. https://doi.org/10.1378/chest.32.4.455.
66. Thomas JP, Baughn CO, Wilkinson RG, Shepherd RG. 1961. A new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2=-(ethylenediimino)-di-L-butanol). Am Rev Respir Dis 83: 891-893.
67. Vall-Spinosa A, Lester W, Moulding T, Davidson PT, Mc Clatchy JK. 1970. Rifampin in the treatment of drug-resistant Mycobacterium tuberculosis infections. N Engl J Med 283:616-621. https://doi.org/10.1056/ NEJM197009172831202.
68. Combs DL, O’Brien RJ, Geiter LJ. 1990. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 112:397-406. https://doi.org/10.7326/0003-4819-76-3-112-6-397.
69. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. 2010. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830-1843. https://doi.org/10.1016/S0140-6736(10)60410-2.
70. Young K, Jayasuriya H, Ondeyka JG, Herath K, Zhang C, Kodali S, Galgoci A, Painter R, Brown-Driver V, Yamamoto R, Silver LL, Zheng Y, Ventura JI, Sigmund J, Ha S, Basilio A, Vicente F, Tormo JR, Pelaez F, Youngman P, Cully D, Barrett JF, Schmatz D, Singh SB, Wang J. 2006. Discovery of Fab H/Fab F inhibitors from natural products. Antimicrob Agents Chemother 50:519-526. https://doi.org/10.1128/AAC.50.2.519-526.2006.
71. Wang J, Soisson SM, Young K, Shoop W, Kodali S, Galgoci A, Painter R, Parthasarathy G, Tang YS, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H, Ondeyka J, Herath K, Zhang C, Hernandez L, Allocco J, Basilio A, Tormo JR, Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, Gill C, Silver LL, Hermes JD, Bartizal K, Barrett J, Schmatz D, Becker JW, Cully D, Singh SB. 2006. Platensimycin is a selective Fab F inhibitor with potent antibiotic properties. Nature 441:358-361. https:// doi.org/10.1038/nature04784.
72. Watve MG, Tickoo R, Jog MM, Bhole BD. 2001. How many antibiotics are produced by the genus Streptomyces? Arch Microbiol 176:386-390. https://doi.org/10.1007/s002030100345.
73. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schäberle TF, Hughes DE, Epstein S, Jones M, Lazarides L, Steadman VA, Cohen DR, Felix CR, Fetterman KA, Millett WP, Nitti AG, Zullo AM, Chen C, Lewis K. 2015. A new antibiotic kills pathogens without detectable resistance. Nature 517:455-459.
74. Lewis K. 2013. Platforms for antibiotic discovery. Nat Rev Drug Discov 12:371-387. https://doi.org/10.1038/nrd3975.
75. Stebbins RB, Graessle OE, Robinson HJ. 1945. Studies on the absorption and excretion of streptomycin in animals. Exp Biol Med 60:68-73. https://doi.org/10.3181/00379727-60-15094.
76. Smith MI, Mc Closky WT, Emmart EW. 1946. Influence of streptomycin and Promin on proliferation of tubercle bacilli in the tissues of albino rat. Exp Biol Med 62:157-162. https://doi.org/10.3181/00379727-62-15406.
77. Hart PD. 1946. Chemotherapy of tuberculosis—part II. Br Med J 2:849-855. https://doi.org/10.1136/bmj.2.4483.849.
78. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323:1215-1218. https://doi.org/10.1126/science.1167498.
79. Sotgiu G, D’Ambrosio L, Centis R, Tiberi S, Esposito S, Dore S, Spanevello A, Migliori GB. 2016. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci 17:373. https://doi.org/10.3390/ijms17030373.
80. Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A. 2013. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 188:608-612. https://doi.org/10.1164/rccm.201304-0753OC.
81. Drlica K, Zhao X. 2007. Mutant selection window hypothesis updated. Clin Infect Dis 44:681-688. https://doi.org/10.1086/511642.
82. Malik M, Chavda K, Zhao X, Shah N, Hussain S, Kurepina N, Kreiswirth BN, Kerns RJ, Drlica K. 2012. Induction of mycobacterial resistance to quinolone class antimicrobials. Antimicrob Agents Chemother 56: 3879-3887. https://doi.org/10.1128/AAC.00474-12.
83. Milstein M, Lecca L, Peloquin C, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD. 2016. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis 16:453. https://doi.org/10.1186/s12879-016-1790-x.
84. Cohen NR, Lobritz MA, Collins JJ. 2013. Microbial persistence and the road to drug resistance. Cell Host Microbe 13:632-642. https://doi.org/ 10.1016/j.chom.2013.05.009.
85. Vogwill T, Comfort AC, Furió V, Mac Lean RC. 2016. Persistence and resistance as complementary bacterial adaptations to antibiotics. J Evol Biol 29:1223-1233. https://doi.org/10.1111/jeb.12864.
86. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S, Wallace MR; Triservice AIDS Clinical Consortium. 2006. Comparisons of causes of death and mortality rates among HIVinfected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 41: 194-200. https://doi.org/10.1097/01.qai.0000179459.31562.16.
87. Kohli A, Shaffer A, Sherman A, Kottilil S. 2014. Treatment of hepatitis C: a systematic review. JAMA 312:631-640. https://doi.org/10.1001/jama.2014.7085.
88. Fox W, Mitchison DA. 1975. Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 111:845-848.
89. Fox W. 1981. Whither short-course chemotherapy? Br J Dis Chest 75: 331-357. https://doi.org/10.1016/0007-0971(81)90022-X.